CPRIT PDR — Texas Device and Diagnostics Company
Funds Texas firms developing cancer diagnostics, companion tools, and biomarkers for clinical deployment.
Eligibility · United States · US-TX
The CPRIT Texas Device and Diagnostics Company RFA is a Product Development Research mechanism administered by the Cancer Prevention and Research Institute of Texas, which allocates approximately $70 million per fiscal year across its four product development tracks. The Device and Diagnostics RFA funds Texas-based for-profit companies developing devices and assays for cancer detection, diagnosis, prognosis, monitoring, and treatment. Eligible products include companion diagnostics, diagnostic tests for high-risk early lesions, and cancer prevention and control biomarkers. Applicants are typically near IDE, 510(k), or PMA regulatory submission. The program shares the same underlying structure as the Therapeutics RFA: awards are grants backed by Texas General Obligation bonds, require matching funds from the company, and require a revenue-sharing agreement with the state.
The performance period is three years, extendable to allow full fund expenditure. Companies headquartered outside Texas may apply but must commit to relocating to Texas as a condition of the award. The application process follows the same two-stage structure used across CPRIT's product development programs: a preliminary application consisting of a two-page executive summary, a sixteen-slide deck, and a one-page aims and budget summary is submitted when the portal is open, reviewed by the Product Development Review Council (PDRC), and a decision is issued within three to five weeks. Invited applicants then complete a full application and a Zoom presentation to the review panel.
Companies most competitive for the Device and Diagnostics RFA will have a device or assay with strong analytical and clinical validation data and a clear regulatory pathway to market. Because the mechanism specifically calls for applicants near IDE, 510(k), or PMA submission, the development stage bar is meaningfully higher than for earlier-phase grants. The revenue-sharing obligation is a firm contract requirement and should be factored into commercial planning before applying. Applicants should confirm portal status and current RFA terms at cprit.texas.gov prior to submission.
Cancer detection, diagnosis, prognosis, monitoring, and treatment devices and assays — including companion diagnostics and early-lesion tests — for Texas companies near regulatory submission.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline